Compare PACK & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | QTTB |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 450.1M |
| IPO Year | 2017 | 2018 |
| Metric | PACK | QTTB |
|---|---|---|
| Price | $3.73 | $8.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.08 | ★ $39.60 |
| AVG Volume (30 Days) | 504.1K | ★ 827.2K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | $53,737,000.00 |
| Revenue This Year | $9.87 | N/A |
| Revenue Next Year | $9.00 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $1.91 |
| 52 Week High | $7.81 | $23.57 |
| Indicator | PACK | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 30.86 |
| Support Level | $3.31 | $5.12 |
| Resistance Level | $3.82 | $16.85 |
| Average True Range (ATR) | 0.18 | 0.70 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 4.68 | 22.26 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).